Mylan Pharmaceuticals Pvt Ltd has launched DURART R 450, a fixed-dose combination (FDC) drug comprising darunavir/ritonavir 400/50mg for treatment of adults and adolescents weighing more than 40kg, with HIV-1 in India.

This is one of the first FDC drugs available to patients in India. Alternative treatments require patients to take two drugs separately from two different bottles.

Commenting on the launch, Rakesh Bamzai, President, India and Emerging Markets, Mylan, said: “The launch of DURART R 450 is another step forward in Mylan’s endeavour to provide much- needed HIV treatment solutions to those in need. Patients with HIV-1 will now have access to the fixed-dose combination therapy which may improve the overall patient treatment outcomes.”

Darunavir and ritonavir are HIV protease inhibitors and can be used in combination for patients failing first and second-line regimens during the management of HIV-1 infection. Darunavir is currently available in India in 600 mg and 800 mg dose forms and ritonavir is available in the 100 mg and 50 mg dose forms.

Globally, Mylan supplies life-saving antiretroviral (ARV) medicines to nearly 50 per cent of the men, women and children living with HIV in more than 100 developing countries. The company’s ARV portfolio includes 14 APIs and 50 finished dosage forms in first-line, second-line and paediatric formulations.

A couple of days ago Hetero, a generic pharmaceutical company with a portfolio of ARVs, also announced the launch of the two-in-one FDC drug in the domestic market.

Related Topics
comment COMMENT NOW